AI Breakthrough Brief

OpenAI researcher Miles Wang is in talks to launch a $2B AI drug discovery startup focused on repurposing existing drugs. Separately, Deep Origin uses virtual humans and AI simulations to reduce drug failure rates, backed by a $31.7M ARPA contract. Both signal growing AI investment in biotech.